ClinicalTrials.gg
CompletedNCT00794794Updated Feb 16, 2022

Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)

A Phase 3 interventional study of Desloratadine (Clarinex) and Cetirizine (Zyrtec) in Allergic Rhinitis, sponsored by Organon and Co. Completed. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Rhinitis, Allergic by Organon & Co. — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic · Organon & Co..

Enrollment
9th of 20
204 · median 197
Started
2004
with 4 others
Phase 3
14 of 21
none open now
Registered
15th of 21
by date

Among the 21 studies in Rhinitis, Allergic by Organon & Co., this one is the 9th largest by enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2004, is one of 14 in phase 3, and was the 15th registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

None of the 21 studies in Rhinitis, Allergic by Organon & Co. is open now. The open studies under Rhinitis, Allergic, anywhere →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies in Rhinitis, Allergic by Organon & Co. as a file.
02

Study summary

This study was conducted to compare the taste acceptability of Zyrtec syrup with desloratadine syrup in children. Children between 6 and 11 years of age received 5 mL of each syrup, separated by 15 to 20 minutes on a single day.

Read the detailed description

This study is a cross-over study design.

03

Conditions studied

  • Allergic Rhinitis

Browse trials for

04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must be:

  • Between 6 and 11 years of age in good general health
  • Premenarcheal if female

Exclusion criteria

Exclusion Criteria:

Subjects who:

  • Have known allergies or sensitivities to either of the drug formulations
  • Have a medical condition that may interfere with the subject's ability to discriminate between tastes
  • Have used any antihistamines within 24 hours prior to dosing
  • Were taking sedatives, tranquilizers, or monoamine oxidase inhibitor drugs
  • Were involved in another clinical or market research study within the past 30 days
05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Desloratadine and Cetirizine Crossover

    To compare the preference in taste between desloratadine and cetirizine.

    Drug: Desloratadine (Clarinex) · Drug: Cetirizine (Zyrtec)

Interventions

06

What researchers measure

Primary outcomes

  1. Taste acceptability as determined from smiley-face scale of 1 (frowning child) to 5 (happy child face).

    Time frame: During the only study visit

Secondary outcomes

  1. Taste flavor preference between bubble-gum, banana-grape, or grape flavors

    Time frame: During the only study visit

  2. Adverse Events

    Time frame: During the only study visit

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2008
First posted
Nov 20, 2008
Start
Nov 2004
Primary completionActual
Nov 2004
CompletionActual
Nov 2004
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00794794
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Nov 20, 2008
Start date
Nov 2004
Primary completion
Nov 2004
Completion
Nov 2004
Last update
Feb 16, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desloratadine · Cetirizine

Start the discussion